JP2003530074A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003530074A5 JP2003530074A5 JP2001513369A JP2001513369A JP2003530074A5 JP 2003530074 A5 JP2003530074 A5 JP 2003530074A5 JP 2001513369 A JP2001513369 A JP 2001513369A JP 2001513369 A JP2001513369 A JP 2001513369A JP 2003530074 A5 JP2003530074 A5 JP 2003530074A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- epitope
- cell
- epitopes
- ctl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 description 56
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 52
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 52
- 210000003719 b-lymphocyte Anatomy 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 21
- 108091006116 chimeric peptides Proteins 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000028993 immune response Effects 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000002077 nanosphere Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- -1 including Substances 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010086377 HLA-A3 Antigen Proteins 0.000 description 1
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 1
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 1
- 108010091938 HLA-B7 Antigen Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14686999P | 1999-08-03 | 1999-08-03 | |
| US60/146,869 | 1999-08-03 | ||
| PCT/US2000/021222 WO2001008636A2 (en) | 1999-08-03 | 2000-08-03 | Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003530074A JP2003530074A (ja) | 2003-10-14 |
| JP2003530074A5 true JP2003530074A5 (enExample) | 2007-10-04 |
| JP4658423B2 JP4658423B2 (ja) | 2011-03-23 |
Family
ID=22519334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001513369A Expired - Fee Related JP4658423B2 (ja) | 1999-08-03 | 2000-08-03 | Ｈｅｒ−２タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US7060284B1 (enExample) |
| EP (1) | EP1246597B1 (enExample) |
| JP (1) | JP4658423B2 (enExample) |
| AU (1) | AU6620300A (enExample) |
| WO (1) | WO2001008636A2 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0991403B1 (en) | 1997-01-30 | 2003-04-02 | Chiron Corporation | Use of microparticles with adsorbed antigen to stimulate immune responses |
| US6833438B1 (en) | 1999-06-01 | 2004-12-21 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US20030149531A1 (en) | 2000-12-06 | 2003-08-07 | Hubert Rene S. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US20060052321A1 (en) | 2002-04-05 | 2006-03-09 | Raitano Arthur B | Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer |
| JP4658423B2 (ja) | 1999-08-03 | 2011-03-23 | ザ オハイオ ステイト ユニバーシティ | Ｈｅｒ−２タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド |
| CA2405290C (en) | 2000-04-13 | 2011-06-21 | Bio Life Science Forschungs Und Entwicklungsgesellschaft Mbh | Vaccine against cancerous diseases |
| EP1236740B1 (de) * | 2001-02-28 | 2012-07-18 | Bio Life Science Forschungs- und Entwicklungsges.m.b.H. | Vakzine gegen Krebserkrankungen, die mit dem HER-2/neu Onkogen assoziiert sind |
| US7531180B2 (en) | 2001-05-31 | 2009-05-12 | Novartis Vaccines And Diagnostics, Inc | Chimeric alphavirus replicon particles |
| US20030108565A1 (en) * | 2001-07-10 | 2003-06-12 | Johnson Mark E. | Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| WO2004028551A1 (en) * | 2002-09-24 | 2004-04-08 | The Burnham Institute | Novel agents that modulate eph receptor activity |
| AU2002951853A0 (en) * | 2002-10-04 | 2002-10-24 | Commonwealth Scientific And Industrial Research Organisation | Crystal structure of erbb2 and uses thereof |
| JPWO2005007694A1 (ja) * | 2003-07-16 | 2007-09-20 | 株式会社グリーンペプタイド | ＨＥＲ２／ｎｅｕペプチドおよびその治療上の用途 |
| WO2005043155A1 (en) | 2003-10-21 | 2005-05-12 | Cedars-Sinai Medical Center | System and method for the treatment of cancer, including cancers of the central nervous system |
| WO2005076972A2 (en) * | 2004-02-05 | 2005-08-25 | The Ohio State University Research Foundation | Chimeric vegf peptides |
| JP2008504292A (ja) | 2004-06-24 | 2008-02-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | 免疫増強用の化合物 |
| EP2583678A3 (en) | 2004-06-24 | 2013-11-13 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
| GB2434367B (en) * | 2004-10-05 | 2010-05-12 | Diversa Corp | Improved vaccines |
| CN100381460C (zh) * | 2004-11-30 | 2008-04-16 | 北京市肿瘤防治研究所 | Her-2模拟抗原表位及含有该表位的肽 |
| WO2006079055A2 (en) * | 2005-01-24 | 2006-07-27 | Neurosystec Corporation | Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues |
| US7582438B2 (en) | 2005-01-27 | 2009-09-01 | Burnham Institute For Medical Research | EphB receptor-binding peptides |
| WO2006138675A2 (en) | 2005-06-15 | 2006-12-28 | The Ohio State University Research Foundation | Her-2 peptides |
| JP2009511636A (ja) | 2005-10-18 | 2009-03-19 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | アルファウイルスレプリコン粒子による粘膜免疫および全身免疫 |
| US8173657B2 (en) | 2006-03-23 | 2012-05-08 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| EP2049568A2 (en) * | 2006-04-07 | 2009-04-22 | Københavns Universitet | Erbb receptor-derived peptide fragments |
| EP1844788B1 (en) * | 2006-04-13 | 2010-07-14 | Bio Life Science Forschungs- und Entwicklungsges.m.b.H. | HER-2/neu multi-peptide vaccine |
| US8267905B2 (en) * | 2006-05-01 | 2012-09-18 | Neurosystec Corporation | Apparatus and method for delivery of therapeutic and other types of agents |
| US7803148B2 (en) * | 2006-06-09 | 2010-09-28 | Neurosystec Corporation | Flow-induced delivery from a drug mass |
| US20080145439A1 (en) * | 2006-07-31 | 2008-06-19 | Neurosystec Corporation | Nanoparticle drug formulations |
| US7972602B2 (en) * | 2006-08-11 | 2011-07-05 | Dendreon Corporation | Promiscuous HER-2/Neu CD4 T cell epitopes |
| WO2008039874A2 (en) | 2006-09-26 | 2008-04-03 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
| WO2008039974A2 (en) | 2006-09-28 | 2008-04-03 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
| EP2722336A1 (en) | 2007-06-01 | 2014-04-23 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Vaccine for the prevention of breast cancer relapse |
| JP2011525477A (ja) * | 2008-03-04 | 2011-09-22 | リクイディア・テクノロジーズ・インコーポレーテッド | 免疫調節剤粒子および処置方法 |
| DK2328923T3 (en) | 2008-09-02 | 2016-03-21 | Cedars Sinai Medical Center | CD133 epitopes |
| US20100234283A1 (en) | 2009-02-04 | 2010-09-16 | The Ohio State University Research Foundation | Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use |
| EP2292258A1 (en) * | 2009-08-18 | 2011-03-09 | Pevion Biotech Ltd. | Multiepitope vaccine for Her2/neu-associated cancers |
| KR20130121699A (ko) | 2010-05-28 | 2013-11-06 | 테트리스 온라인, 인코포레이티드 | 상호작용 혼성 비동기 컴퓨터 게임 기반구조 |
| WO2011154863A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Inc. | Her-2 peptides and vaccines |
| GB201019467D0 (en) * | 2010-11-17 | 2010-12-29 | Biotecnol Sa | Therapeutic agent |
| CA2898474A1 (en) | 2013-02-14 | 2014-08-21 | Immunocellular Therapeutics, Ltd. | Cancer vaccines and vaccination methods |
| WO2014131019A2 (en) | 2013-02-25 | 2014-08-28 | Ohio State Innovation Foundation | Her-1, her-3 and igf-1r compositions and uses thereof |
| JP6077641B2 (ja) * | 2013-03-08 | 2017-02-08 | 大鵬薬品工業株式会社 | 新規ｃｔｌエピトープ５連結ペプチド |
| AU2014336638C1 (en) | 2013-10-18 | 2020-09-17 | Novartis Ag | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| CN106456735B (zh) * | 2014-03-28 | 2021-06-29 | 华盛顿大学商业中心 | 乳腺癌和卵巢癌疫苗 |
| CN105884885A (zh) * | 2015-02-15 | 2016-08-24 | 深圳信立泰药业股份有限公司 | 一种多肽疫苗的水合盐及其制备方法和含有该盐的药物制品 |
| RS63080B1 (sr) * | 2015-04-17 | 2022-04-29 | Biolife Science Qld Ltd | Kompozicija vakcine i njene upotrebe |
| WO2018116074A1 (en) | 2016-12-19 | 2018-06-28 | Kabiri Mona | Chimeric peptides against htlv-1 |
| SG11201911430PA (en) | 2017-07-04 | 2020-01-30 | Curevac Ag | Novel nucleic acid molecules |
| JP2021501572A (ja) | 2017-10-19 | 2021-01-21 | キュアバック アーゲー | 新規な人工核酸分子 |
| CN109748952B (zh) * | 2018-05-02 | 2020-09-15 | 中国药科大学 | 辅助性表位肽及其应用 |
| TW202039534A (zh) | 2018-12-14 | 2020-11-01 | 美商美國禮來大藥廠 | KRAS變體mRNA分子 |
| WO2025088088A1 (en) | 2023-10-27 | 2025-05-01 | CureVac SE | Rna composition for improving cell therapy |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| EP0474727B1 (en) | 1989-05-19 | 1997-07-23 | Genentech, Inc. | Her2 extracellular domain |
| CA2074720C (en) | 1990-01-26 | 2002-07-23 | Martin A. Cheever | Immune reactivity to expressed activated oncogenes for diagnosis and treatment of malignancy |
| IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
| AU687750B2 (en) | 1992-09-28 | 1998-03-05 | Wyeth Holdings Corporation | Method of enhancing cell mediated immune responses |
| CA2145391A1 (en) * | 1992-09-30 | 1994-04-14 | Vernon C. Stevens | Vaccines and antigenic conjugates |
| US5869445A (en) | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
| US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| US6410022B1 (en) | 1995-05-01 | 2002-06-25 | Avant Immunotherapeutics, Inc. | Modulation of cholesteryl ester transfer protein (CETP) activity |
| NZ331596A (en) | 1996-04-03 | 1999-07-29 | Pepresearch A S | Non-dendritic backbone peptide carrier |
| CN100415772C (zh) * | 1996-10-18 | 2008-09-03 | 基因技术股份有限公司 | 抗ErbB2抗体 |
| ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| ES2320311T3 (es) * | 1999-05-14 | 2009-05-21 | Genentech, Inc. | Tratamiento con anticuerpos anti-erbb2. |
| JP4658423B2 (ja) * | 1999-08-03 | 2011-03-23 | ザ オハイオ ステイト ユニバーシティ | Ｈｅｒ−２タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド |
| US20030235594A1 (en) | 1999-09-14 | 2003-12-25 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
| PL365789A1 (pl) | 2000-08-14 | 2005-01-10 | Corixa Corporation | Kompozycje oraz sposoby leczenia i diagnozowania nowotworów związanych z Her-2/neu |
| WO2006138675A2 (en) | 2005-06-15 | 2006-12-28 | The Ohio State University Research Foundation | Her-2 peptides |
-
2000
- 2000-08-03 JP JP2001513369A patent/JP4658423B2/ja not_active Expired - Fee Related
- 2000-08-03 US US09/632,036 patent/US7060284B1/en not_active Expired - Fee Related
- 2000-08-03 EP EP00953823.2A patent/EP1246597B1/en not_active Expired - Lifetime
- 2000-08-03 WO PCT/US2000/021222 patent/WO2001008636A2/en not_active Ceased
- 2000-08-03 AU AU66203/00A patent/AU6620300A/en not_active Abandoned
-
2006
- 2006-06-09 US US11/423,194 patent/US7666430B2/en not_active Expired - Fee Related
-
2010
- 2010-01-06 US US12/683,114 patent/US8110657B2/en not_active Expired - Fee Related
-
2012
- 2012-02-06 US US13/366,546 patent/US20120201841A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003530074A5 (enExample) | ||
| Lowell et al. | Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants. | |
| KR100808313B1 (ko) | 비형 간염 코어 항원 융합 단백질 | |
| DE68928251T2 (de) | Cs-Peptide von P. Falciparum als allgemeines t-Zellen-Epitop | |
| AU764961B2 (en) | Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides | |
| ES2337113B1 (es) | Empleo de la hemaglutinina del virus de la peste porcina africana como adyuvante. | |
| JP2004538332A5 (enExample) | ||
| DE60130877T2 (de) | Modifizierte peptide enthaltende pharmazeutische präparationen | |
| JP2006504653A5 (enExample) | ||
| DE4192335C2 (de) | T-Zell-Epitope | |
| AU712468B2 (en) | Method for enhancing the immunogenicity of an immunogenic compound or hapten, and use thereof for preparing vaccines | |
| FR2718452A1 (fr) | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. | |
| JP2017513956A5 (enExample) | ||
| CA2457140A1 (en) | Beta-amyloid-analogue - t-cell epitope vaccine | |
| EP0755259A4 (en) | CHIMERAL cDNA CLONES OF THE VIRUS OF INFECTIOUS BURSAL DISEASE, EXPRESSION PRODUCTS AND Vaccines Based On Them | |
| JP2010535026A (ja) | 多量体マルチエピトープインフルエンザワクチン | |
| RU2007119319A (ru) | Наборы антигенов полипептида, угнетающего секрецию желудка (gip), и их применение | |
| JP2009500298A5 (enExample) | ||
| US20250262286A1 (en) | Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response | |
| JP2002536384A (ja) | Ｔヘルパー細胞エピトープ | |
| Haeuw et al. | The recombinant Klebsiella pneumoniae outer membrane protein OmpA has carrier properties for conjugated antigenic peptides | |
| CA2337754A1 (en) | Recombinant multivalent malarial vaccine against plasmodium falciparum | |
| Arnon | Peptides as immunogens: prospects for synthetic vaccines | |
| JP3135060B2 (ja) | ヘモフィルスインフルエンザｂ型菌の外皮膜タンパク質Ｐ２の部分断片を用いた接合体 | |
| TWI823051B (zh) | 針對垂體腺苷酸環化酶激活胜肽的胜肽免疫原及其預防和治療偏頭痛的製劑 |